Residency · Residency · Ophthalmology

Diabetic Macular Edema: Current Treatment Paradigms

Definition and Classification

Clinically Significant Macular Edema (CSME) -- ETDRS Definition

The ETDRS established the original clinical definition of clinically significant macular edema, which includes any of the following: retinal thickening at or within 500 micrometers of the foveal center, hard exudates at or within 500 micrometers of the foveal center with adjacent retinal thickening, or retinal thickening of one disc area or larger when any part of the thickened area lies within one disc diameter of the foveal center. While this definition guided management for decades, it was based on biomicroscopic examination and is now largely historical. Modern management of diabetic macular edema is guided by optical coherence tomography, which provides objective, quantitative assessment of macular thickness and morphology.

OCT-Based Classification

The critical clinical distinction is between center-involving and non-center-involving DME. Center-involving DME (CI-DME) is defined as thickening that involves the central subfield, the 1 mm diameter zone centered on the fovea. A central subfield thickness exceeding approximately 300 micrometers, though the exact threshold varies by OCT device, is considered abnormal. Center-involving DME with associated vision loss is the key treatment trigger for anti-VEGF therapy. Non-center-involving DME refers to macular thickening that spares the central subfield. If vision remains good, observation with close monitoring is appropriate. Focal laser photocoagulation may be considered if the edema is progressive or threatens to encroach on the center.

Morphological Patterns on OCT

OCT reveals several distinct morphological patterns of diabetic macular edema. Diffuse retinal thickening produces a sponge-like appearance of the retinal layers. Cystoid macular edema manifests as well-defined hyporeflective intraretinal cysts. Subretinal fluid appears as a hyporeflective space beneath the neurosensory retina. Vitreomacular traction can contribute to or perpetuate macular edema by exerting mechanical force on the macula. Hard exudates appear as hyperreflective foci within the outer retinal layers. These patterns can coexist in the same eye and have implications for treatment selection and prognosis.

<image>OCT B-scans demonstrating different morphological patterns of diabetic macular edema: diffuse thickening, cystoid spaces, subfoveal fluid, and vitreomacular traction</image>

Anti-VEGF Therapy

Agents

Four anti-VEGF agents are used in the treatment of diabetic macular edema. Ranibizumab (Lucentis) is a humanized monoclonal antibody Fab fragment that binds all isoforms of VEGF-A. Aflibercept (Eylea) is a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor with higher binding affinity than ranibizumab. Bevacizumab (Avastin) is a full-length monoclonal antibody used off-label but widely employed due to its substantially lower cost. Faricimab (Vabysmo) is a bispecific antibody that simultaneously targets both VEGF-A and angiopoietin-2 (Ang-2), addressing two distinct pathways involved in vascular leakage and instability.

Key Trials

Anti-VEGF Agents for DME

DRCR.net Protocol T

Protocol T was a landmark head-to-head comparison of aflibercept, bevacizumab, and ranibizumab for center-involving DME. The results stratified by baseline visual acuity revealed an important clinical distinction. In eyes with baseline visual acuity of 20/50 or worse, aflibercept was superior to both bevacizumab and ranibizumab at one year, with mean visual acuity improvements of 18.9 letters, 11.8 letters, and 14.2 letters, respectively. In eyes with better baseline acuity of 20/32 to 20/40, there was no significant difference among the three agents. At two years, aflibercept and ranibizumab produced similar outcomes, and both remained superior to bevacizumab in the worse-vision subgroup. The practical takeaway is that aflibercept is preferred when presenting vision is 20/50 or worse, while bevacizumab is a reasonable and cost-effective choice for milder cases.

DRCR.net Protocol I

Protocol I compared ranibizumab combined with prompt or deferred laser against laser alone and triamcinolone combined with laser for center-involving DME. Anti-VEGF therapy proved superior to laser alone, establishing intravitreal anti-VEGF injection as first-line therapy for CI-DME and displacing focal laser from its long-held position as the standard of care.

YOSEMITE and RHINE Trials

The YOSEMITE and RHINE trials evaluated faricimab, the bispecific antibody targeting both VEGF-A and Ang-2, for diabetic macular edema. Faricimab was non-inferior to aflibercept at one year, and more than 50% of faricimab-treated patients achieved dosing intervals of every 16 weeks. This potential for reduced treatment burden is a meaningful advantage for both patients and healthcare systems.

Treatment Protocols

Three main dosing strategies are used in clinical practice. Fixed monthly dosing, with injections every four weeks, provides maximum efficacy but imposes the highest treatment burden. Pro re nata (PRN) dosing treats only when recurrence is detected on monitoring visits, reducing the number of injections but still requiring frequent clinic visits for assessment. The treat-and-extend (TAE) approach has become the most common real-world strategy, balancing efficacy with injection burden. With TAE, injections are given monthly until the macula is dry on OCT, then the interval between visits is extended by two-week increments. If fluid recurs, the interval is shortened. Typical maintenance intervals range from every 8 to every 16 weeks.

<image>Treatment algorithm flowchart for center-involving diabetic macular edema showing initial anti-VEGF therapy, response assessment at 3-6 injections, and decision pathways for good responders, partial responders, and non-responders</image>

Corticosteroid Therapy

Intravitreal Dexamethasone Implant (Ozurdex)

The dexamethasone intravitreal implant (Ozurdex) is a biodegradable sustained-release device that delivers 0.7 mg of dexamethasone over approximately three to four months. It is indicated for DME in pseudophakic eyes, in anti-VEGF non-responders, and for post-surgical cystoid macular edema. The principal risks are IOP elevation, which occurs in 30 to 35% of patients, and cataract progression in phakic eyes.

Fluocinolone Acetonide Implant (Iluvien / Retisert)

Iluvien is a 0.19 mg non-biodegradable insert that releases low-dose fluocinolone acetonide for up to 36 months. It is FDA-approved for DME in patients who have previously been treated with corticosteroids without developing a clinically significant IOP rise -- essentially a steroid-response screening criterion. Retisert is a 0.59 mg surgically implanted device used primarily for chronic non-infectious uveitis rather than DME. The risks of long-term intravitreal corticosteroid delivery are substantial: steroid-induced glaucoma requiring IOP-lowering therapy occurs in up to 40% of patients, and cataract formation is nearly universal in phakic eyes.

When to Use Corticosteroids in DME

Corticosteroids occupy a second-line role in DME management. They are most appropriate in pseudophakic eyes with persistent edema despite adequate anti-VEGF therapy, in anti-VEGF non-responders or partial responders, in patients who cannot tolerate the frequency of injection visits that anti-VEGF requires, and when a significant inflammatory component is present, such as in postoperative or uveitic settings. Corticosteroids should not be used as first-line therapy in phakic patients because of the risks of cataract and glaucoma.

Focal/Grid Laser Photocoagulation

Historical Role

The ETDRS established focal laser photocoagulation as the original standard of care for diabetic macular edema. Focal treatment involves direct laser application to individual leaking microaneurysms, while grid treatment is applied to areas of diffuse leakage and thickening. The ETDRS demonstrated that laser treatment reduced the risk of moderate vision loss by approximately 50%, a landmark finding that guided management for over two decades before the anti-VEGF era.

Current Role

Focal laser has been largely supplanted by anti-VEGF therapy as first-line treatment for center-involving DME. However, it retains a role in several clinical scenarios. It remains useful for non-center-involving DME with circinate exudates threatening the fovea, where targeted focal treatment can arrest the advance of lipid toward the center. It can be used as an adjunct to anti-VEGF therapy to reduce injection frequency, as demonstrated by the deferred laser arm of Protocol I. It also remains valuable in resource-limited settings where access to anti-VEGF agents is difficult or cost-prohibitive. When laser is used today, modified lighter burns are preferred over the heavier burns described in the original ETDRS protocol.

Surgical Management

Vitrectomy for DME

Pars plana vitrectomy is indicated when vitreomacular traction or an epiretinal membrane contributes to macular edema. In these cases, relieving the mechanical traction can allow the edema to resolve. Internal limiting membrane peeling may improve anatomical outcomes. Vitrectomy is not routinely indicated for DME in the absence of a tractional component, but it should be considered when anti-VEGF therapy and corticosteroids have failed and OCT demonstrates a taut posterior hyaloid face exerting traction on the macula.

<image>Fundus photograph showing focal laser treatment marks around leaking microaneurysms in non-center-involving diabetic macular edema, with circinate ring of hard exudates</image>

Emerging Therapies

Extended-Durability Anti-VEGF

The treatment burden of frequent intravitreal injections has driven the development of longer-acting formulations. High-dose aflibercept (8 mg) was evaluated in the PHOTON trial and demonstrated that extended dosing intervals of every 12 to 16 weeks could be achieved. Anti-VEGF gene therapy, involving intravitreal or subretinal delivery of transgenes encoding VEGF-inhibiting proteins, aims to provide continuous endogenous anti-VEGF production. The port delivery system, a surgically implanted reservoir that continuously releases anti-VEGF medication, was initially developed for AMD and is under investigation for DME.

Novel Targets

Beyond VEGF, several novel therapeutic targets are under investigation. Angiopoietin-2 inhibition, already realized clinically with faricimab, addresses vascular instability. Integrin antagonists, kallikrein-kinin pathway inhibitors, and Tie2 activators represent additional approaches targeting the complex pathophysiology of diabetic vascular disease.

Clinical Pearls

OCT should always be obtained before making treatment decisions in DME, as visual acuity alone is insufficient to guide management -- eyes with significant macular thickening may retain surprisingly good acuity, and conversely, eyes with poor acuity may have minimal edema if photoreceptor damage has already occurred. The key takeaway from Protocol T is straightforward: for eyes with visual acuity of 20/50 or worse, aflibercept is the preferred agent, while for eyes with better acuity, all three agents perform comparably, making cost a reasonable factor in the decision. Switching anti-VEGF agents is a reasonable strategy after three to six injections with suboptimal response, as some eyes respond better to one agent than another. Corticosteroids are second-line agents and should be reserved for pseudophakic eyes or anti-VEGF non-responders. Systemic factors -- hemoglobin A1c, blood pressure, renal function, and lipid levels -- significantly influence the response to local DME treatment, and optimizing these factors is an essential component of management. Patients should be counseled that hard exudates may persist or even appear to worsen initially after anti-VEGF therapy, because as the fluid is absorbed the lipid residue remains and may become more concentrated. Bilateral DME is common, and both eyes should always be examined.

References

• Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema (Protocol T). N Engl J Med. 2015;372(13):1193-1203.
• Elman MJ, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser for diabetic macular edema (Protocol I). Ophthalmology. 2010;117(6):1064-1077.
• Wykoff CC, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in DME (YOSEMITE and RHINE). Ophthalmology. 2022;129(6):607-621.
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS Report No. 1. Arch Ophthalmol. 1985;103(12):1796-1806.
• American Academy of Ophthalmology. Basic and Clinical Science Course, Section 12: Retina and Vitreous.

Read this lecture as Markdown